AID Life Science Holdings Limited provided earnings guidance for the nine months ended September 30, 2020. For the period, the company expected to record 20% to 30% decrease in loss as compared to that for the nine months ended September 30, 2019. The decrease in loss was mainly attributable to decrease in research and development costs and amortisation of intangible assets after the disposal of GeneSort; and loss on disposal of subsidiaries was recognised for the nine months ended September 30, 2019, whereas gain on disposal of subsidiaries was recognised during the Period.